Pembrolizumab 2023 drug donation policy

Pembrolizumab is an antibody drug, also known as an anti-PD-1 drug, that is usually given via intravenous injection and is treated according to your doctor's instructions and specific disease conditions. It is approved for the treatment of several types of cancer, including non-small cell lung cancer, melanoma, Hodgkin lymphoma, and urothelial carcinoma. Pembrolizumab enhances the ability of immune cells to attack cancer cells by inhibiting the PD-1 receptor in the immune system. The PD-1 receptor is an immune checkpoint that plays an important role in regulating the activity of immune cells and balancing immune responses. Some cancer cells can use the PD-1 pathway to evade immune attack. Pembrolizumab blocks this signaling pathway, allowing immune cells to attack and eliminate cancer cells more effectively.

PembrolizumabThe original drug has been launched in China, and the price of 100mg/4ml per box may be around 15,000 yuan. This drug is a strictly controlled drug and has not yet been included in the medical insurance. Patients may need to understand the drug donation policy of pembrolizumab through relevant institutions, and reduce the price, thereby reducing the burden on patients and accelerating the progress of drug treatment. Pembrolizumab The price of the European version of the original drug 100mg/4ml per box may be around RMB 25,000, and the price of the Turkish version of 100mg/4ml per box may be around 10,000 RMB (the price may fluctuate due to the exchange rate). The ingredients of the original drugs at home and abroad are basically the same, and they are expensive. There are currently no generic versions of Pembrolizumab available overseas.